Sobetirome及其酰胺前药Sob-AM2在Mct8缺陷脑中发挥甲状腺模拟作用
该研究在Mct8/Dio2双敲除幼年小鼠中系统给予索贝替罗(sobetirome)1 mg/kg/天或其酰胺前药Sob-AM2 0.3 mg/kg/天共7天,评估其入脑及甲状腺模拟作用。结果显示Sob-AM2使脑内索贝替罗含量较原药组高1.8倍、血浆低2.5倍,两药均降低血浆T4和T3,并上调脑内多个T3依赖基因表达。
要点
- Sob-AM2使Mct8/Dio2KO小鼠脑内索贝替罗含量较索贝替罗组高1.8倍、血浆低2.5倍。
- 索贝替罗与Sob-AM2均大幅降低Mct8/Dio2KO小鼠血浆T4和T3水平。
- 两药均上调Mct8/Dio2KO小鼠脑内Hr、Abcd2、Mme、Flywch2等T3依赖基因表达。
核心结论
- 索贝替罗及其酰胺前药Sob-AM2在缺乏Mct8时仍可进入脑内并发挥甲状腺模拟作用,调节T3依赖基因表达;外周给药导致循环T4和T3耗竭,因此有望同时针对MCT8缺陷的脑部甲状腺功能减退与外周甲状腺功能亢进。
研究设计与样本
- 幼年野生型(Wt)小鼠与Mct8/Dio2双敲除(Mct8/Dio2KO)小鼠接受每日注射溶媒、索贝替罗1 mg/kg体重/天或Sob-AM2 0.3 mg/kg体重/天,共7天;用液相色谱-串联质谱测定索贝替罗含量,用特异性放射免疫法测定T4和T3,用实时PCR测定心、肝、大脑皮质中T3依赖基因表达。
主要发现
- 与索贝替罗治疗相比,Sob-AM2治疗使Mct8/Dio2KO动物脑内索贝替罗含量高1.8倍、血浆中低2.5倍。
- 索贝替罗与Sob-AM2治疗均大幅降低Mct8/Dio2KO小鼠血浆T4和T3水平。
- Mct8/Dio2KO小鼠肝脏Dio1和Ucp2基因表达发生改变,且未受上述治疗影响。
- 心脏中Hcn2表达在两种类似物治疗后升高,Atp2a2表达未升高。
- 索贝替罗与Sob-AM2治疗均增加Mct8/Dio2KO小鼠脑内Hr、Abcd2、Mme和Flywch2等T3依赖基因表达。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Loss of function mutations in the thyroid hormone (TH)-specific cell membrane transporter, the monocarboxylate transporter 8 (MCT8), lead to profound psychomotor retardation and abnormal TH serum levels, with low thyroxine (T4) and high triiodothyronine (T3). Several studies point to impaired TH transport across brain barriers as a crucial pathophysiological mechanism resulting in cerebral hypothyroidism. Treatment options for MCT8-deficient patients are limited and are focused on overcoming the brain barriers. The aim of this study was to evaluate the ability of the TH analog sobetirome and its prodrug Sob-AM2 to access the brain and exert thyromimetic actions in the absence of Mct8. METHODS: Juvenile wild-type (Wt) mice and mice lacking Mct8 and deiodinase type 2 (Mct8/Dio2KO) were treated systemically with daily injections of vehicle, 1 mg of sobetirome/kg body weight/day, or 0.3 mg of Sob-AM2/kg body weight/day for seven days. Sobetirome content was measured using liquid chromatography-tandem mass spectrometry, and T4 and T3 levels by specific radioimmunoassays. The effect of sobetirome treatment in the expression of T3-dependent genes was measured in the heart, liver, and cerebral cortex by real-time polymerase chain reaction. RESULTS: Sob-AM2 treatment in Mct8/Dio2KO animals led to 1.8-fold more sobetirome content in the brain and 2.5-fold less in plasma in comparison to the treatment with the parent drug sobetirome. Both sobetirome and Sob-AM2 treatments in Mct8/Dio2KO mice greatly decreased plasma T4 and T3 levels. Dio1 and Ucp2 gene expression was altered in the liver of Mct8/Dio2KO mice and was not affected by the treatments. In the heart, Hcn2 but not Atp2a2 expression was increased after treatment with the analogs. Interestingly, both sobetirome and Sob-AM2 treatments increased the expression of several T3-dependent genes in the brain such as Hr, Abcd2, Mme, and Flywch2 in Mct8/Dio2KO mice. CONCLUSIONS: Sobetirome and its amide prodrug Sob-AM2 can access the brain in the absence of Mct8 and exert thyromimetic actions modulating the expression of T3-dependent genes. At the peripheral level, the administration of these TH analogs results in the depletion of circulating T4 and T3. Therefore, sobetirome and Sob-AM2 have the potential to address the cerebral hypothyroidism and the peripheral hyperthyroidism characteristic of MCT8 deficiency.
引用
- Bárez-López S, Hartley MD, Grijota-Martínez C, et al. Sobetirome and its Amide Prodrug Sob-AM2 Exert Thyromimetic Actions in Mct8-Deficient Brain. Thyroid. 2018. PMID: 29845892. doi:10.1089/thy.2018.0008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。